Valneva COVID-19 vaccine begins manufacturing at Scotland plant

28 January 2021

French specialty vaccine company Valneva (Euronext: VLA) saw its shares gain almost 5% to 9.58 euros by midday, after the company announced it has started commercial production of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, at its manufacturing plant in Livingstone, West Lothian, Scotland.

This was in parallel to the ongoing clinical studies, in order to optimize the timeline for potential deliveries of the vaccine. The Phase I/II clinical study is now fully enrolled and is expected to report initial results in April 2021.

VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. A total of 150 healthy adults aged 18 to 55 years have been recruited for the Phase I/II study which commenced mid December 2020, the French biotech firm said, but gave no indication as to when it would apply for regulatory approval for VAL2001.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK